Table 3. Biodistribution of ⁸⁹Zr-FSC-ZEGFR:2377 and ⁸⁹Zr-DFO-ZEGFR:2377 in EGFR-Expressing A431 Tumor Xenografted Female BALB/C nu/nu Mice Expressed as Percentage of Injected Dose per Gram Tissue (% ID/g; Mean ± SD; n = 4)^a.

	89Zr-FSC-ZEGFR:2377 (radiolabeling at 85 °C)		89Zr-DFO-ZEGFR:2377 (radiolabeling at 85 °C)		89Zr-DFO-ZEGFR:2377 (radiolabeling at RT)42
organs	3 h	24 h	3 h	24 h	3 h	24 h
blood	1.02 ± 0.29§	0.31 ± 0.08+,§	0.57 ± 0.1*,#	0.25 ± 0.07+,#	2.0 ± 0.38	0.7 ± 0.07+
salivary gland	1.18 ± 0.15	1.08 ± 0.19	0.82 ± 0.11*	0.68 ± 0.18*	0.99 ± 0.25	0.75 ± 0.06§
lung	1.43 ± 0.06	0.88 ± 0.1+	0.83 ± 0.09*,#	0.6 ± 0.09*,#	1.6 ± 0.14	0.98 ± 0.24+
liver	6.71 ± 1.38	5.71 ± 0.94	3.05 ± 0.18*,#	2.37 ± 0.24+,*	4.13 ± 0.86§	2.7 ± 0.18+,§
spleen	1.51 ± 0.23	1.38 ± 0.14	0.9 ± 0.13*	0.96 ± 0.13*	0.8 ± 0.12§	0.86 ± 0.19§
colon	1.32 ± 0.09	1.19 ± 0.2	1.12 ± 0.2	0.81 ± 0.12*	1.15 ± 0.32	0.89 ± 0.23
kidney	291.04 ± 19.8	251.54 ± 23.87	283.5 ± 19.01	305.78 ± 63.6	239.05 ± 17.21	232.27 ± 10.56
tumor	8.42 ± 1.53*,§	5.25 ± 0.83+,*,§	5.9 ± 0.48#	3.31 ± 0.57+	4.25 ± 0.63	2.58 ± 0.47+
muscle	0.30 ± 0.04	0.24 ± 0.03+	0.21 ± 0.02*,#	0.18 ± 0.02*,#	0.31 ± 0.02	0.25 ± 0.03+
bone	1.00 ± 0.09	0.99 ± 0.26	0.54 ± 0.23#	1.0 ± 0.31	0.94 ± 0.16	1.77 ± 0.61+

^aStatistical analysis was performed using the Student’s t test with P values indicating significant (P < 0.05) difference (+) between 3 and 24 h, (*) between ⁸⁹Zr-FSC-ZEGFR:2377 (85 °C) and ⁸⁹Zr-DFO-ZEGFR:2377 (85 °C), (§) between ⁸⁹Zr-FSC-ZEGFR:2377 (85 °C) and ⁸⁹Zr-DFO-ZEGFR:2377 (RT) and (#) between ⁸⁹Zr-DFO-ZEGFR:2377 (85 °C) and ⁸⁹Zr-DFO-ZEGFR:2377 (RT) at corresponding time points.